← back to search

Andrew Dodson

Office for National Statistics · US
🔎 Find collaborators in Cancer Research · Genetics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Cancer Research · Genetics
Research interest
Research interests include Breast Cancer Treatment Studies, Estrogen and related hormone effects, Advanced Breast Cancer Therapies, and HER2/EGFR in Cancer Research.
h-index
43
citations
6,438
works
155
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

UK participation in the UK National External Quality Assessment Scheme for mismatch repair immunohistochemistry: insights from the last decade.
2026cited by 0position: contributordoi
Inter-rater agreement of HER2-low scores between expert breast pathologists and the Visiopharm digital image analysis application (HER2 APP, CE2797).
2025cited by 2position: contributordoi
Variability in Sodium Content of Takeaway Foods: Implications for Public Health and Nutrition Policy
2025cited by 0position: contributordoi
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
2023cited by 0position: contributordoi
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
2023cited by 0position: contributordoi
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
2023cited by 0position: contributordoi
Supplementary Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
2023cited by 0position: contributordoi
Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
2023cited by 0position: contributordoi
Data from Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
2023cited by 0position: contributordoi
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
Modern Pathology 2022cited by 49position: middledoi
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast Cancer.
2022cited by 15position: contributordoi
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
2021cited by 499position: contributordoi
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
JNCI Journal of the National Cancer Institute 2020cited by 712position: middledoi
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
The Lancet Oncology 2020cited by 311position: middledoi
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Nature Communications 2020cited by 258position: middledoi
External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
2020cited by 21position: contributordoi
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
Journal of Clinical Oncology 2018cited by 233position: middledoi
Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients
The Journal of Pathology Clinical Research 2018cited by 65position: firstdoi
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
Proceedings of the National Academy of Sciences 2017cited by 113position: middledoi
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration
npj Breast Cancer 2016cited by 152position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

— · 11 papers (2020–2026)Maggie Chon U. Cheang · Royal Marsden Hospital7 papers (2022–2023)Lucy Kilburn · CRUK Lung Cancer Centre of Excellence7 papers (2022–2023)Mitch Dowsett · Breast Cancer Now5 papers (2017–2020)John M.S. Bartlett · Edinburgh Cancer Research2 papers (2018–2020)Anthony Skene · Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust2 papers (2020–2020)Judith M. Bliss · Institute of Cancer Research2 papers (2020–2020)Abigail Evans · Eunice Kennedy Shriver National Institute of Child Health and Human Development2 papers (2020–2020)Carmine De Angelis · Baylor College of Medicine1 papers (2017–2017)David L. Rimm · Yale Cancer Center1 papers (2020–2020)Rachel Schiff · Baylor College of Medicine1 papers (2017–2017)Michael Hubank · Royal Marsden Hospital1 papers (2020–2020)Raghavan Vidya · The Royal Wolverhampton NHS Trust1 papers (2020–2020)Myles Brown · Harvard University1 papers (2017–2017)Carsten Denkert · Frankfurt Cancer Institute1 papers (2020–2020)Ian Smith · Queensland Health1 papers (2020–2020)— · 1 papers (2020–2020)Ros Cutts · Institute of Cancer Research1 papers (2020–2020)Lisa M. McShane · National Cancer Institute1 papers (2020–2020)Alex Pearson · University of California, Santa Cruz1 papers (2020–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Cancer Research · Genetics →